Takeda Reports Q2 2026 Results with Revenue Headwinds Amid Transformation Program
Takeda Pharmaceutical Company Limited (TAK) reported second-quarter fiscal 2026 results characterized by a slight decline in core revenue to JPY 2.4 trillion, representing a 1% decrease at constant exchange rates. The company noted that headwinds within its mature and off-patent portfolio are not yet fully offset by the growth of new product launches, which currently account for 4% of total revenue. Despite these challenges, Takeda raised its full-year revenue and profit forecasts due to favorable foreign exchange adjustments and deferred tax asset recognition. The company is also undergoing a significant organizational redesign, including the reduction of 3,000 positions, as part of a transformation program aimed at achieving JPY 100 billion in gross procurement savings.
Tickers: $TAK
Topics: cash flow earnings report layoffs operating profit revenue guidance